文献速递肾移植

肾移植术后常规抗HLA抗体筛查的效用

Utility of Routine Post Kidney Transplant Anti-HLA Antibody Screening.
PubMed 文献 · Kidney Int Rep · 2024-02-18

该回顾性研究纳入1072例低免疫风险肾移植受者,共进行4611次抗HLA检测,中位随访8年,77例(7.2%)出现dnDSA,其中45.5%在术后第一年检出;系统性筛查检出率仅1.08%,且系统性DSA检测后活检常见活动性和慢性AMR。结论提示低免疫风险且无致敏事件患者中系统性筛查检出dnDSA罕见,尤其术后1年后。

要点

  • 低免疫风险肾移植受者中dnDSA总患病率7.2%,近半数在术后第一年检出。
  • 系统性筛查dnDSA检出率仅1.08%,95%的dnDSA患者病历中可找到致敏事件。
  • 系统性DSA检测后活检中活动性AMR和慢性AMR分别占17.9%和15.4%。

核心结论

  • 低免疫风险且无致敏事件的肾移植患者中,系统性筛查检出dnDSA罕见,尤其术后1年后。
  • 系统性年度筛查dnDSA对较临床指征检测更早发现AMR的临床效用似乎有限。

研究设计与样本

  • 回顾性队列研究,纳入1072例低免疫风险肾移植受者(非HLA致敏且无既往肾移植史)。
  • 共进行4611次抗HLA检测,中位随访8年(IQR 5-11年)。

主要发现

  • 95%的dnDSA患者病历中可识别出致敏事件。
  • 系统性筛查检测4267次,检出dnDSA 46次,检出率1.08%。
  • 系统性DSA检测后活检中活动性AMR占17.9%,慢性AMR占15.4%。

关键数值与推荐

  • 低免疫风险定义:非HLA致敏且无既往肾移植史。
  • dnDSA总患病率7.2%(77/1072),系统性筛查检出率1.08%(46/4267)。

临床怎么用

  • 对低免疫风险且无致敏事件的肾移植受者,系统性年度dnDSA筛查的检出收益较低,尤其术后1年后。
  • 临床可结合致敏事件病史决定是否进行抗HLA抗体检测,而非对所有低风险患者常规年度筛查。

局限性

  • 回顾性研究设计。
  • 研究对象限于低免疫风险患者,结论不宜外推至高免疫风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: De novo donor-specific antibody (dnDSA) is a strong biomarker associated with the development of antibody-mediated rejection (AMR) and graft loss after kidney transplantation. This procedure is expensive; however, systematic annual screening was recommended by some national organ transplant agencies or societies even though its clinical utility was not clearly established. METHODS: To address this question, we retrospectively assessed the incidence of dnDSA according to the test justification (clinically indicated or systematic) in a cohort of low-immunological risk patients, defined by being nonhuman leukocyte antigen (non-HLA)-sensitized and having no previous kidney transplants. RESULTS: A total of 1072 patients, for whom 4611 anti-HLA tests were performed, were included in the study. During the follow-up period of 8 (interquartile range, IQR: 5-11) years, 77 recipients developed dnDSA (prevalence of 7.2%). Thirty-five of these dnDSAs (45.5%) were detected during the first year posttransplantation. In 95% of patients with dnDSA, an immunizing event was identified in their medical records. dnDSA was detected in 46 of 4267 systematic screening tests (1.08%) performed. Active and chronic AMR were frequently observed in biopsies performed after systematic DSA testing (17.9% and 15.4%, respectively). CONCLUSION: Our results suggest that the detection by systematic screening of dnDSA in low-immunological risk kidney transplant patients without sensitizing events is a rare event, especially after 1 year. Moreover, in real life, systematic annual screening for dnDSA, seems having a limited impact to detect AMR at an earlier stage compared to patients in whom dnDSA was detected after a clinically indicated test.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Salhi S, Congy-Jolivet N, Hebral AL, et al. Utility of Routine Post Kidney Transplant Anti-HLA Antibody Screening. Kidney Int Rep. 2024. PMID: 38707794. doi:10.1016/j.ekir.2024.02.1394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。